Month: October 2019


AliveCor and Huami Collaborate to Bring the Next Generation ECG

Shots: The companies together formed a multi-faceted global strategic alliance which combines the technologies of both the companies to deliver a new generation of medical functionality to wearable devices Huami will utilize AliveCor’s Intelligent, medical grade, heart care platform in its smart watches and heart trackers and will provide AliveCor’s AI driven subscription services and […]Read More


Astellas Signs an Exclusive License Agreement with Pandion to Deliver

Shots: Pandion to receive up to $45M as upfront and payments for research and preclinical activities, ~$750M as development and commercial milestone and royalties on global sales of the therapies developed via collaboration Pandion to be responsible for drug designing and discovery of bispecific therapies utilizing its modular immune effector and tissue tether platform while […]Read More


Pear Therapeutics Signs an Agreement with Ironwood to Assess Prescription

Shots: The companies collaborated to explore developing PDTs for the treatment of patients with selected indications within the gastrointestinal space The focus of the agreement is to merge Pear’s expertise in PDTs with Ironwood’s GI franchise and clinical expertise and to expand Pear’s portfolio outside the central nervous system The collaboration will provide an opportunity […]Read More


Biogen and Alkermes’ Vumerity (diroximel fumarate) Receive FDA’s Approval for

Shots: The FDA’s approval is based on NDA submitted under the 505(b)(2) filing pathway and contain data from P-III EVOLVE-MS-1 study assessing Vumerity in patients with relapsing-remitting MS In Nov’2017, Biogen and Alkermes collaborated to develop & commercialize Vumerity under which Alkermes to receive $150M and royalties on WW sales of Vumerity for the 5yrs. […]Read More


LEO Pharma Signs an Option Agreement with Ubiquigent to Access

Shots: Ubiquigent to receive up front, option exercise fee and milestone payment. Leo Pharma to get an option to access two novel therapies The partnership will strengthen Leo Pharma’s research capabilities and disease understanding and extending its expertise in medical dermatology worldwide The option agreement follows 2018 agreement signed b/w Ubiquigent and LEO Pharma to […]Read More


Novartis Reports FDA’s Hold on P-I/II Intrathecal Study Evaluating Zolgensma/AVXS-101

Shots: The partial hold on clinical study for intrathecal administration of AVXS-101 follows the findings of the pre-clinical study demonstrated dorsal root ganglia (DRG) mononuclear cell inflammation accompanied by neuronal cell body degeneration or loss The partial hold does not have any impact on marketed Zolgensma or AVXS-101 (IV) clinical studies and will remain available […]Read More